Flavonoid quercetin and its glucuronide and sulfate conjugates bind to 67-kDa laminin receptor and prevent neuronal cell death induced by serum starvation.
67-kDa laminin receptor
Epigallocatechin-3-gallate
Neuroprotection
Quercetin
Quercetin-3-O-glucuronide
Quercetin-3-O-sulfate
Journal
Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516
Informations de publication
Date de publication:
03 09 2023
03 09 2023
Historique:
received:
20
05
2023
accepted:
01
06
2023
pmc-release:
03
09
2024
medline:
18
7
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
Quercetin, a dietary flavonoid, has been shown to protect against various neurodegenerative diseases with mechanisms largely unknown. After oral administration, quercetin is rapidly conjugated, and the aglycone is not detectable in the plasma and brain. However, its glucuronide and sulfate conjugates are present only at low nanomolar concentrations in the brain. Since quercetin and its conjugates have limited antioxidant capability at low nanomolar concentrations, it is crucial to determine whether they induce neuroprotection by binding to high-affinity receptors. Previously we found that (-)-epigallocatechin-3-gallate (EGCG), a polyphenol from green tea, induces neuroprotection by binding to the 67-kDa laminin receptor (67LR). Therefore, in this study, we determined whether quercetin and its conjugates bind 67LR to induce neuroprotection and compared their ability with EGCG. Based on the quenching of intrinsic tryptophan fluorescence of peptide G (residues 161-180 in 67LR), we found quercetin, quercetin-3-O-glucuronide, and quercetin-3-O-sulfate bind to this peptide with a high affinity comparable to EGCG. Molecular docking using the crystal structure of 37-kDa laminin receptor precursor supported the high-affinity binding of all these ligands to the site corresponding to peptide G. A pretreatment with quercetin (1-1000 nM) did not effectively protect Neuroscreen-1 cells from death induced by serum starvation. Contrarily, a pretreatment with low concentrations (1-10 nM) of quercetin conjugates better protected these cells than quercetin and EGCG. The 67LR-blocking antibody substantially prevented neuroprotection by all these agents, suggesting the role of 67LR in this process. Collectively, these studies reveal that quercetin induces neuroprotection primarily through its conjugates via high affinity binding to 67LR.
Identifiants
pubmed: 37300941
pii: S0006-291X(23)00736-2
doi: 10.1016/j.bbrc.2023.06.007
pmc: PMC10527810
mid: NIHMS1909221
pii:
doi:
Substances chimiques
Flavonoids
0
Quercetin
9IKM0I5T1E
Glucuronides
0
Sulfates
0
Polyphenols
0
Receptors, Laminin
0
Catechin
8R1V1STN48
Cell Adhesion Molecules
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-123Subventions
Organisme : NINDS NIH HHS
ID : R21 NS116720
Pays : United States
Organisme : NINDS NIH HHS
ID : RF1 NS130681
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Rev Neurosci. 2019 Jul 26;30(5):555-572
pubmed: 30753166
Molecules. 2022 Aug 11;27(16):
pubmed: 36014370
Free Radic Biol Med. 2001 Jun 1;30(11):1274-85
pubmed: 11368925
J Med Chem. 2002 Sep 26;45(20):4460-70
pubmed: 12238925
Free Radic Biol Med. 2011 Oct 1;51(7):1329-36
pubmed: 21741473
Oncotarget. 2017 Dec 13;9(5):5958-5978
pubmed: 29464047
J Neurochem. 2005 Jun;93(5):1157-67
pubmed: 15934936
Life Sci. 2019 May 1;224:109-119
pubmed: 30914316
PLoS One. 2012;7(5):e37942
pubmed: 22666419
Biochemistry. 2012 Jun 19;51(24):4807-21
pubmed: 22640394
J Biol Chem. 2008 Apr 4;283(14):9424-34
pubmed: 18199750
Free Radic Biol Med. 2014 Jan;66:24-35
pubmed: 23747930
Ageing Res Rev. 2008 Jan;7(1):1-7
pubmed: 18162444
Mol Biol Evol. 1998 Aug;15(8):1017-25
pubmed: 9718729
Arch Biochem Biophys. 2014 Sep 1;557:11-7
pubmed: 24893148
Am J Clin Nutr. 2005 Jan;81(1 Suppl):268S-276S
pubmed: 15640490
J Nutr. 2008 Sep;138(9):1615-21
pubmed: 18716159
Biochem Biophys Res Commun. 2000 Jun 24;273(1):50-3
pubmed: 10873562
Genes Nutr. 2012 Apr;7(2):99-109
pubmed: 22012276
J Nutr Biochem. 2022 Dec;110:109129
pubmed: 35977663
Free Radic Biol Med. 2016 Jan;90:145-57
pubmed: 26603095
Oncotarget. 2015 Jul 20;6(20):18116-33
pubmed: 26062445
Drug Metab Rev. 2017 May;49(2):105-138
pubmed: 28266877
Nat Struct Mol Biol. 2004 Apr;11(4):380-1
pubmed: 15024383
J Biol Chem. 1992 Sep 5;267(25):17743-7
pubmed: 1387642
Biochem Med. 1979 Aug;22(1):70-5
pubmed: 496933
Br J Anaesth. 2014 Dec;113(6):935-44
pubmed: 24985077
Bio Protoc. 2019 Jun 05;9(11):e3253
pubmed: 33654778
Biochem Biophys Res Commun. 2014 Feb 28;445(1):218-24
pubmed: 24508265
J Ethnopharmacol. 2012 Sep 28;143(2):383-96
pubmed: 22820241
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
FASEB J. 2013 Feb;27(2):769-81
pubmed: 23097297
Biomolecules. 2019 Dec 30;10(1):
pubmed: 31905923
Molecules. 2015 Jan 05;20(1):608-24
pubmed: 25569517
Biochem Biophys Res Commun. 2018 Jan 1;495(1):230-237
pubmed: 29108990
Free Radic Biol Med. 2004 Apr 1;36(7):838-49
pubmed: 15019969
J Biol Chem. 2008 Feb 8;283(6):3002-3005
pubmed: 18063583
Oxid Med Cell Longev. 2016;2016:2986796
pubmed: 26904161
Neuropharmacology. 2015 Jun;93:134-45
pubmed: 25666032
Biol Rev Camb Philos Soc. 2016 May;91(2):288-310
pubmed: 25630983
Biosci Rep. 2012 Dec 20;33(1):113-24
pubmed: 23137297
Front Pharmacol. 2021 Jun 17;12:665031
pubmed: 34220504
J Nutr. 2008 Aug;138(8):1417-20
pubmed: 18641184
Biochemistry. 1989 Sep 5;28(18):7476-86
pubmed: 2531008
J Biol Chem. 2012 Oct 5;287(41):34694-708
pubmed: 22879598
Dose Response. 2020 Jul 15;18(3):1559325820936170
pubmed: 32728352